Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders
出版年份 2021 全文链接
标题
Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders
作者
关键词
-
出版物
JOURNAL OF MEDICINAL CHEMISTRY
Volume 64, Issue 24, Pages 18054-18081
出版商
American Chemical Society (ACS)
发表日期
2021-12-03
DOI
10.1021/acs.jmedchem.1c01476
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The PROTACtable genome
- (2021) Melanie Schneider et al. NATURE REVIEWS DRUG DISCOVERY
- AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild-type KRAS and BRAF by destabilizing Aurora kinase B
- (2021) Jia Xu et al. Cancer Discovery
- Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders
- (2020) Meng Cheng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of First-in-class Protein Arginine Methyltransferase 5 (PRMT5) Degraders
- (2020) Yudao Shen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)
- (2019) Jiantao Hu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
- (2019) Blake E. Smith et al. Nature Communications
- Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-mutant Pancreatic and Colorectal Cancer
- (2019) Jörn Weisner et al. CANCER RESEARCH
- Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6
- (2019) Baishan Jiang et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome
- (2019) Kim M. Keppler-Noreuil et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models
- (2019) M Catarina Silva et al. eLife
- Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader
- (2019) Hannah Tovell et al. ACS Chemical Biology
- Covalent-Allosteric Inhibitors to Achieve Akt Isoform-Selectivity
- (2019) Lena Quambusch et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
- (2019) Longchuan Bai et al. CANCER CELL
- Targeting AKT for cancer therapy
- (2019) Maryam Shariati et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader
- (2019) Jieli Wei et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeted protein degradation: expanding the toolbox
- (2019) Matthieu Schapira et al. NATURE REVIEWS DRUG DISCOVERY
- A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
- (2019) Sajid Khan et al. NATURE MEDICINE
- Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands
- (2018) Lara N. Gechijian et al. Nature Chemical Biology
- Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach
- (2018) Zuni I. Bassi et al. ACS Chemical Biology
- The Akt pathway in oncology therapy and beyond (Review)
- (2018) George Nitulescu et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Waste disposal—An attractive strategy for cancer therapy
- (2017) Jemilat Salami et al. SCIENCE
- Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping
- (2017) Xiaofeng Dai et al. Journal of Cancer
- The PI3K/AKT Pathway as a Target for Cancer Treatment
- (2016) Ingrid A. Mayer et al. Annual Review of Medicine
- Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor
- (2016) Jean-Marc Lapierre et al. JOURNAL OF MEDICINAL CHEMISTRY
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
- (2015) GEORGE MIHAI NITULESCU et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer
- (2015) Khanh Do et al. INVESTIGATIONAL NEW DRUGS
- Prime time for PROTACs
- (2015) Raymond J Deshaies Nature Chemical Biology
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
- (2014) Eric S. Fischer et al. NATURE
- ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays
- (2014) Camilo Guzmán et al. PLoS One
- Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor
- (2014) Melissa Dumble et al. PLoS One
- Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo
- (2014) Yuanyuan Zhao et al. Drug Design Development and Therapy
- A kinase-independent function of AKT promotes cancer cell survival
- (2014) Igor Vivanco et al. eLife
- Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases
- (2013) Matt Addie et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification and Quantification of AKT Isoforms and Phosphoforms in Breast Cancer Using a Novel Nanofluidic Immunoassay
- (2013) Demetris C. Iacovides et al. MOLECULAR & CELLULAR PROTEOMICS
- Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
- (2013) Jiri Polivka et al. PHARMACOLOGY & THERAPEUTICS
- Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors
- (2012) James F. Blake et al. JOURNAL OF MEDICINAL CHEMISTRY
- Loss of PTEN Permits CXCR4-Mediated Tumorigenesis through ERK1/2 in Prostate Cancer Cells
- (2010) M. A. Chetram et al. MOLECULAR CANCER RESEARCH
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
- (2009) Teresa A. Soucy et al. NATURE
- Inhibitor hijacking of Akt activation
- (2009) Tatsuya Okuzumi et al. Nature Chemical Biology
- Deregulation of the Akt Pathway in Human Cancer
- (2008) Eriko Tokunaga et al. CURRENT CANCER DRUG TARGETS
- Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a Novel Inhibitor of AKT Kinase
- (2008) Dirk A. Heerding et al. JOURNAL OF MEDICINAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started